跳至主要内容
临床试验/DRKS00009247
DRKS00009247已完成不适用

ZARAMulticentre, non-interventional study of the efficacy and safety of zoledronic acid in skeletal related tumors (SRE) and hypercalcemia of malignancy (TIH) - ZARA

AxioNovo Gmbh0 个研究点目标入组 495 人开始时间: 2015年8月18日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AxioNovo Gmbh
入组人数
495

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • 18 Years old
  • - Informed consent was singed correctly
  • - Patient has advanced tumor disease which extended to the skeletal or elevated calcium serum levels as a result of malignant tumor growth
  • -Therapeutic decision was made independently from a possible NIS enrollment
  • - Patient does not participate in a clinical trial

排除标准

  • - Contraindications to the use of zoledronic acid according to the SmPC.
  • - The current therapy was started more than 12 weeks ago.
  • - The patient is participating in a clinical trial at the same time.
  • - Pregnancy is present or the patient is breastfeeding.

研究者

发起方
AxioNovo Gmbh

相似试验